[Changes of urinary deoxypyridinoline crosslink/creatinine in rats after ovariectomy and anti-osteoporotic intervention].
OBJECTIVE
To observe the changes of urinary deoxypyridinoline crosslink/creatinine (UDpd/Cr) in rats after OVX and intervention by estrogen and bisphosphonate and investigate the possible application of deoxypyridinoline in osteoporosis diagnosis and treatment.


METHODS
40 female 6-month-old virginal Wistar rats were divided into 5 groups, ovariectomized or sham ovariectomized. (1) Ovxb (n = 8): sacrificed at 6 weeks after OVX; (2) Sham (n = 8): sham ovariectomized; (3) Ovxe (n = 8): sacrificed at 14 weeks after OVX; (4) O + E (n = 9):OVX + 17 beta estradiol [20 micrograms/(kg.d) ih]; (5) O + C (n = 7):OVX + cimadronate [0.2 mg/(kg.d)]; Treatment started 6 weeks after OVX and lasted 8 weeks. Rats in group 2-5 were sacrificed at 14 weeks after OVX. Urinary and serum biochemical parameters were measured, pQCT scanning of femur, bone biomechanical test in femur were determined.


RESULTS
OVX resulted in increasing of UDpd/Cr 133.3% (P < 0.01). The ratio of UCa/Cr also increased in OVX groups but without any significant compared with Sham (P > 0.05). UDpd/Cr were reduced by 54.6% and 51.8% (P < 0.01) in O + E, O + C group respectively compared with Ovxe. The significant negative correlationships were found between UDpd/Cr and bone mass, BMD and biomechanic characteristics.


CONCLUSIONS
UDpd/Cr ratio is a sensitive bone resorption marker, a marked changes were observed when the rats ovariectomized or treated with estradiol and cimadronate. There were best correlation between UDpd/Cr and bone mineral density and bone biomechanic characteristics. It is fair to apply UDpd/Cr ratio for osteoporosis diagnosis and treatment.
Hu
Ying-ying
YY
Department of Endocrinology, PUMC Hospital, CAMS, PUMC, Beijing 100730, China.
Xia
Wei-bo
WB
Liu
Huai-cheng
HC
Meng
Xun-wu
XW
Zhou
Xue-ying
XY
Xing
Xiao-ping
XP
D000596:Amino Acids / Q000652:urine*; D000818:Animals; D015519:Bone Density; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use*; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D010024:Osteoporosis / Q000188:drug therapy / Q000652:urine*; D010052:Ovariectomy; D051381:Rats; D017208:Rats, Wistar
D000596:Amino Acids; D004164:Diphosphonates; C071542:cimadronate; D004958:Estradiol; C036020:deoxypyridinoline; D003404:Creatinine